"Patients who received Herceptin had a statistically significant improvement in progression-free survival," the Swiss drug maker said in a statement.

Advertisement

HER2-positive breast cancer is a particularly aggressive form of hormone receptor-positive breast cancer; the prognosis for these patients is typically bleak. Hormone receptor-positive breast cancers account for two-thirds of all cases worldwide, and roughly a quarter of these cases are also HER2-positive. Roche noted that this was the first randomised trial to look at how Herceptin works in this subset of breast cancer patients.

According to the company statement, Herceptin is currently only licensed to treat metastatic cancer - where tumours have spread throughout the body - in the European Union. On the 24th of May 2006 the EU granted approval in Europe for early use of Herceptin in HER2-positive breast cancer.

To date, more than 230 000 breast cancer patients have been treated with Herceptin worldwide, according to the company statement. – (HealthDayNews)

Visit our Breast Centre for more information.

May 2006
 

Print this article on

Rate this article Poor 1 2 3 4 5 Excellent

JOBS

Civil Engineering Technician Gauteng - Johannesburg Financial Manager R380,000-400,000 Per Annum Cost To Company Gauteng - West Rand Treasury Specialist R300,000-380,000 Per Annum Cost To Company Gauteng - Johannesburg JAVA DEVELOPER (YL028 – 04/09) Gauteng DELPHI DEVELOPER (YL023 – 04/09) R320,000-360,000 Per Annum Cost To Company Market Related Gauteng Senior and Lead .NET Developers (C#.NET, Arc, Design, Code.) R300,000-600,000 Per Annum Cost To Company Gauteng - Johannesburg A C# Developer (C Sharp Developer) Gauteng - Johannesburg A C++ Developer (Software Developer) Gauteng - Pretoria Find more jobs Register your CV Post a job